文献速递癫痫

人类颞叶癫痫中mTOR复合物1与2的机制研究

Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.
PubMed 文献 · Ann Neurol · 2018-02-15

该研究分析耐药性颞叶癫痫患者手术切除的海马和颞叶样本,通过蛋白印迹和免疫组化检测mTORC1和mTORC2活性标志物及上下游信号通路,发现两者均显著激活,并识别PI3K和Ras/ERK为潜在上游激活因子,mTORC2过度激活伴随Akt依赖的促生存通路诱导。

要点

  • 人类颞叶癫痫中mTORC1和mTORC2信号均显著上调。
  • PI3K和Ras/ERK通路可能是mTORC1/2的上游激活因子。
  • mTORC2过度激活伴随FoxO3a和GSK3β抑制性磷酸化增加。

核心结论

  • 人类颞叶癫痫中mTOR信号显著失调,mTORC1和mTORC2均激活。
  • 抑制mTORC1而不影响mTORC2的药物可能成为新的抗癫痫发生剂。

研究设计与样本

  • 分析耐药性颞叶癫痫患者手术切除的海马和颞叶样本,以局灶性皮质发育不良II型样本为阳性对照。
  • 采用蛋白印迹定量mTORC1和mTORC2活性标志物及相关信号通路,并用组织学和免疫组化评估结构异常和细胞特异性表达。

主要发现

  • 颞叶癫痫样本中磷酸化mTOR(Ser2448)、磷酸化S6(Ser235/236)、磷酸化S6(Ser240/244)和磷酸化Akt(Ser473)表达显著高于对照。
  • PI3K和Ras/ERK信号通路被识别为mTORC1和mTORC2的潜在上游激活因子。
  • mTORC2过度激活伴随FoxO3a(Ser253)和GSK3β(Ser9)抑制性磷酸化增加,提示Akt依赖的促生存通路诱导。

临床怎么用

  • 提示mTORC1和mTORC2信号通路可作为颞叶癫痫的潜在治疗靶点。
  • 临床可用抑制mTORC1而不损害mTORC2信号的药物(如雷帕霉素及其类似物)可能作为颞叶癫痫的抗癫痫发生剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Temporal lobe epilepsy (TLE) is a chronic epilepsy syndrome defined by seizures and progressive neurological disabilities, including cognitive impairments, anxiety, and depression. Here, human TLE specimens were investigated focusing on the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) and complex 2 (mTORC2) activities in the brain, given that both pathways may represent unique targets for treatment. METHODS: Surgically resected hippocampal and temporal lobe samples from therapy-resistant TLE patients were analyzed by western blotting to quantify the expression of established mTORC1 and mTORC2 activity markers and upstream or downstream signaling pathways involving the two complexes. Histological and immunohistochemical techniques were used to assess hippocampal and neocortical structural abnormalities and cell-specific expression of individual biomarkers. Samples from patients with focal cortical dysplasia (FCD) type II served as positive controls. RESULTS: We found significantly increased expression of phospho-mTOR (Ser2448), phospho-S6 (Ser235/236), phospho-S6 (Ser240/244), and phospho-Akt (Ser473) in TLE samples compared to controls, consistent with activation of both mTORC1 and mTORC2. Our work identified the phosphoinositide 3-kinase and Ras/extracellular signal-regulated kinase signaling pathways as potential mTORC1 and mTORC2 upstream activators. In addition, we found that overactive mTORC2 signaling was accompanied by induction of two protein kinase B-dependent prosurvival pathways, as evidenced by increased inhibitory phosphorylation of forkhead box class O3a (Ser253) and glycogen synthase kinase 3 beta (Ser9). INTERPRETATION: Our data demonstrate that mTOR signaling is significantly dysregulated in human TLE, offering new targets for pharmacological interventions. Specifically, clinically available drugs that suppress mTORC1 without compromising mTOR2 signaling, such as rapamycin and its analogs, may represent a new group of antiepileptogenic agents in TLE patients. Ann Neurol 2018;83:311-327.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Talos DM, Jacobs LM, Gourmaud S, et al. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy. Ann Neurol. 2018. PMID: 29331082. doi:10.1002/ana.25149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。